23 patients with metastatic non oat cell bronchogenic carcinoma (MNOBC) were treated with cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) after radiation therapy. Objective responses were seen in 11 of 23 patients (48%) with a projected median survival time of 12.5 mth for responding patients and patients with stable disease. Lung, liver and cutaneous sites of involvement proved to be highly responsive; bone involvement was less responsive. CAMP is an effective combination in the treatment of MNOBC and its use in patients with less advanced disease should be explored.
|Original language||English (US)|
|Number of pages||6|
|Journal||Cancer Treatment Reports|
|State||Published - Dec 1 1976|
ASJC Scopus subject areas
- Cancer Research